S&P 5007,785.76▼0.2% Nasdaq26,729.16▼0.3% Dow53,732.41▼0.2% Russell 2K3,068.42▲0.5% 10-Yr4.70%+6bp VIX14.25−0.38 WTI$82.40▲1.4% Gold$4,432.00▲1.6% EUR/USD1.157▲0.4% BTC$65,606▲1.4% Nikkei68,309▲1.2%
At close · Fri, Aug 14, 2026
Daily Market Updates.

Earnings

Home›Earnings›Previews›Moderna says its mRNA vaccine prevents cancer recurren…

Moderna says its mRNA vaccine prevents cancer recurrence

The company is pairing the mRNA therapeutic vaccine with Merck’s Keytruda in the experimental treatment described.

Reported · Written up by our desk · Previews

MarketWatch reports that Moderna said its experimental mRNA therapeutic vaccine prevented cancer recurrence in its study, calling the result a breakthrough for personalized medicine.

The company’s candidate described in the coverage combines its mRNA approach with Merck’s cancer drug Keytruda.

MarketWatch also notes that Moderna’s stock rose as the result gained attention.

← Newer storyTech training can worsen burnout for older workers, study finds

More like this

EarningsAnthropic tops $65B annualized revenue run rate ahead of IPO debut
EarningsTesla Cybercab rollout in Austin could pressure ride-hailing margins
EarningsPony AI expands robotaxi fleet as Q2 revenue rises nearly 69%
EarningsRetail earnings week begins with signals on consumer spending
EarningsModerna stock jumps on interim skin cancer trial success

Sources

MarketWatchModerna’s experimental vaccine prevents cancer recurrence, in ‘historic’ win for personalized medicine. Its stock is soaring.
MarketWatchModerna’s experimental vaccine prevents cancer recurrence, in ‘historic’ win for personalized medicine. Its stock is soaring.

Get the close, explained.

One email every trading day: what moved, why it moved, and what's on deck tomorrow. Read in 3 minutes.

Free. Unsubscribe anytime.